The identification of three human metabolites of a peptide-doxorubicin conjugate using HPLC-MS-MS in positive and negative ionization modes

Journal of Chromatographic Science

Volumn 42, Issue 6, 2004, Pages 317-322

  Desai, R B ^a   Schwartz, M S ^a   Matuszewski, B K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; DRUG METABOLITE; LEUCINE DOXORUBICIN; PEPTIDE DOXORUBICIN CONJUGATE; UNCLASSIFIED DRUG;

ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IONIZATION; MASS SPECTROMETRY; NONHUMAN; PROSTATE CANCER; RAT;

CANIS FAMILIARIS;

EID: 3142681640     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/42.6.317     Document Type: Article

References (8)

1. R. DiPaola, J. Rinehart, J. Nemunaitis, S. Ebbinghaus, T. Capana, M. Ciardella, E. Rubin, N. Adams, A. Williams, M. Schwartz, G. Winchell, K. Wickersham, P. Deutsch, and S. Yao. Characterization of a novel prostate specific antigen activated peptide-doxorubicin conjugate in patients with prostate cancer. J. Clin. Oncol. 20(7): 1874-79 (2002).
2. D. DeFeo Jones, V. Garsky, B. Wong, D. Feng, T. Bolyar, K. Haskell, D. Keifer, K. Leander, E. McAvoy, P. Lumma, J. Wai, E. Senderak, S. Motzel, K. Keenan, M. Van Zwieten, J. Lin, R. Freidinger, J. Huff, A. Oliff, and R. Jones. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nature Med. 6: 1248 (2000).
3. M.S. Schwartz and B.K. Matuszewski. Determination of a peptide-doxorubicin, prostate specific antigen activated prodrug, and its active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection; stabilization of the peptide prodrug with EDTA. J. Chromatogr. B 780(1): 171-82 (2002).
4. B. Sinha. Binding specificity of chemically and enzymatically activated anthracycline anticancer agents to nucleic acids. Chem.-Biol. Interactions 30: 67-77 (1980).
5. J. de Jong, C. Munniksma, W. Guerand, A. Bast, and W. Van der Vijgh. Fully automated determination of a new anthracycline N-I-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling. J. Chromatogr. 574: 273-81 (1992).
6. J. de Jong, G. Geijssen, C. Munniksma, J. Vermorken, and W. van der Vijgh. Plasma pharmacodynamics of a new prodrug N-I-leucyldoxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol. 10(12): 1897-1906 (1992).
7. F. Lachatre, P. Marquet, S. Ragot, J. Gaulier, P. Cardot, and J. Dupuy. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B 738: 281-91 (2000).
8. S. Penco, G. Cassinelli, A. Vigevani, P. Zini, G. Rivola, and F. Arcamone. Daunorubicin aldo-keto reductases: Enantioface differential reduction of the side chain carbonyl group of antitumor anthracyclines. Gazzetta Chimica Italiana 115: 195-97 (1985).